Bufalin: A promising therapeutic drug against the cisplatin-resistance of ovarian cancer by targeting the USP36/c-Myc axis
Biochemical and Biophysical Research Communications · 2024
DOI: 10.1016/j.bbrc.2024.150440 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Bing Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecology, Harbin Medical University Cancer Hospital, Harbin, 150081, China. Electronic address: libingjn331@163.com. Hauptthemen laut MEDLINE: Cisplatin, Drug Resistance, Neoplasm, Ovarian Neoplasms, Bufanolides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Cisplatin (DPP) resistance is a severe obstacle to ovarian cancer (OC) treatment. Our research aims to uncover the therapeutic effect and the underlying mechanism of Bufalin against DDP resistance. The cell viability, proliferation capacity, γH2AX expression, and apoptosis ratio were quantified via CCK8 assay, colony formation assay, immunofluorescence, and flow cytometry analysis respectively. Xenografting experiment was performed to detect the tumor growth. Molecular docking was applied to mimic the combination of Bufalin and USP36 protein, and Western blotting was conducted to measure the Bax, Bcl-2, γH2AX, USP36, and c-Myc expression. The c-Myc ubiquitination and half-life were detected via ubiquitination assay and cycloheximide chasing assay. Bufalin treatment notably suppressed the cell viability and colony numbers, and increased the apoptosis ratio and γH2AX level in the DDP treatment group. Bufalin therapy also notably inhibited tumor growth, Bax, Bcl-2, and γH2AX expression in vivo. Moreover, the Bufalin application remarkedly reduced the c-Myc expression and half-life and increased the c-Myc ubiquitination via interaction and subsequent down-regulation of USP36. Knockdown of USP36 reversed the antiproliferative effect and proapoptotic capacity of Bufalin therapy in the DDP treatment group. In conclusion, Bufalin can overcome the DDP resistance in vitro and in vivo via the USP36/c-Myc axis, which innovatively suggests the therapeutic potential of Bufalin against DDP resistance ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynaecology, Harbin Medical University Cancer Hospital, Harbin, 150081, China. Electronic address: libingjn331@163.com.
- Department of Gynaecology, Harbin Medical University Cancer Hospital, Harbin, 150081, China. Electronic address: Shutan19900@163.com.
- Department of Gynaecology, Harbin Medical University Cancer Hospital, Harbin, 150081, China. Electronic address: xiyuherbin@163.com.
- Department of Gynaecology, Harbin Medical University Cancer Hospital, Harbin, 150081, China. Electronic address: Wangyan04010@163.com.
Zitieren
APA
Li, B., Tan, S., Yu, X., & Wang, Y. (2024). Bufalin: A promising therapeutic drug against the cisplatin-resistance of ovarian cancer by targeting the USP36/c-Myc axis. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2024.150440
Vancouver
Li B, Tan S, Yu X, Wang Y. Bufalin: A promising therapeutic drug against the cisplatin-resistance of ovarian cancer by targeting the USP36/c-Myc axis. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2024.150440
BibTeX
@article{Li2024,
author = {Li, Bing and Tan, Shu and Yu, Xi and Wang, Yan},
title = {Bufalin: A promising therapeutic drug against the cisplatin-resistance of ovarian cancer by targeting the USP36/c-Myc axis},
journal = {Biochemical and Biophysical Research Communications},
year = {2024},
doi = {10.1016/j.bbrc.2024.150440}
}
EUVIMED